Ovarian epithelial cancer

23 trials 11 recruiting MedDRA PT
23 Registered trials
11 Recruiting
19 Unique sponsors
36 Unique IMPs
19 Commercial trials
Drug classes (ATC)
— ATC code not specified 11
L Oncology (ATC L) 9
S Ophthalmology/ENT (ATC S) 5
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 14 substances
PARP inhibitor 3 substances
Antimetabolite 2 substances
Antibody-drug conjugate (ADC) 2 substances
CDK inhibitor 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Monoclonal antibody (angiogenesis) 1 substance
Platinum compound 1 substance
Anthracycline 1 substance
Taxane 1 substance
Corticosteroid 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Kinase inhibitor 1 substance
Alkylating agent 1 substance
Topoisomerase I inhibitor 1 substance
SERD 1 substance
Colony-stimulating factor 1 substance
Phase III: 6 Phase II: 4 Phase III/IV: 1 Phase IV: 1 Phase I: 3 Phase I (Other): 3 Phase I (First in Human): 5

Filter these 23 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 23 trials

Phase III

6 trials
  • AstraZeneca AB Commercial
    AZD5335
    2025-520466-22-00 10 countries 2026 n=309
    Recruiting
  • Immunogen Inc. Commercial
    DOXORUBICIN HYDROCHLORIDE; MIRVETUXIMAB SORAVTANSINE; PACLITAXEL; PREDNISOLONE ACETATE; TOPOTECAN
    2024-516111-25-00 1 country 2020 n=1 Orphan
    Ended
  • Merck Sharp & Dohme LLC Commercial
    OLAPARIB; PEMBROLIZUMAB
    2022-502124-52-00 8 countries 2018 n=529
    Ended
  • pharmaand GmbH Commercial
    NIVOLUMAB; RUCAPARIB
    2024-516662-11-00 11 countries 2018 n=257
    Ended
  • Arcagy Gineco Academic
    FILGRASTIM
    2023-508260-30-01 3 countries 2024 n=145
    Recruiting
  • Swiss GO Trial Group Academic
    IMP not specified
    2024-511219-78-00 2 countries 2023 n=300
    Recruiting

Phase II

4 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    CARBOPLATIN; MIRVETUXIMAB SORAVTANSINE; PREDNISOLONE ACETATE
    2022-501220-14-00 3 countries 2023 n=45 Orphan
    Recruiting
  • AbbVie Deutschland GmbH & Co. KG Commercial
    MIRVETUXIMAB SORAVTANSINE; PREDNISOLONE ACETATE
    2024-517184-23-00 4 countries 2025 n=37
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    ABEMACICLIB; ATEZOLIZUMAB; BEVACIZUMAB; COBIMETINIB; CYCLOPHOSPHAMIDE MONOHYDRATE; GIREDESTRANT; INAVOLISIB; IPATASERTIB; LETROZOLE; OLAPARIB; PACLITAXEL; PALBOCICLIB; TRASTUZUMAB EMTANSINE
    2023-508194-89-00 5 countries 2021 n=57 Orphan
    Ended
  • Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic
    HUMAN SERUM ALBUMIN; PERTECHNETATE (99MTC) SODIUM; TECHNETIUM (99MTC)
    2023-505667-37-00 1 country 2023 n=62
    Ended

Phase III/IV

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN HYDROCHLORIDE; GEMCITABINE; MIRVETUXIMAB SORAVTANSINE; PACLITAXEL; PREDNISOLONE ACETATE
    2022-501606-35-01 11 countries 2024 n=110 Orphan
    Recruiting

Phase IV

1 trial
  • Hospices Civils De Lyon Academic
    NIRAPARIB TOSILATE MONOHYDRATE
    2024-513856-14-00 1 country 2021 n=42
    Ended

Phase I

3 trials
  • Merck Healthcare KGaA Commercial
    IMP not specified
    2025-523232-39-00 1 country n=14
    Pending
  • Seagen Inc. Commercial
    IMP not specified
    2023-503389-22-00 4 countries 2022 n=147
    Ended
  • Zymeworks Inc. Commercial
    IMP not specified
    2024-512299-37-00 1 country 2026 n=18
    Recruiting

Phase I (Other)

3 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-506227-29-00 2 countries 2024 n=60
    Recruiting
  • Debiopharm International S.A. Commercial
    IMP not specified
    2023-504824-24-00 1 country 2024 n=47
    Ended
  • Exelixis Inc. Commercial
    IMP not specified
    2023-508267-69-00 5 countries 2023 n=222
    Ended

Phase I (First in Human)

5 trials
  • 858 Therapeutics Inc. Commercial
    ETX-19477
    2024-518326-32-00 3 countries n=28
    Pending
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BRIMONIDINE TARTRATE; IMGN151; PREDNISOLONE ACETATE
    2023-506842-22-00 7 countries 2025 n=176
    Ended
  • BioNTech SE Commercial
    BNT329
    2025-522613-26-00 2 countries 2026 n=90
    Recruiting
  • Exscientia AI Limited Commercial
    BEVACIZUMAB; CAPECITABINE; DOXORUBICIN HYDROCHLORIDE; FULVESTRANT; GTAEXS617; PACLITAXEL
    2023-508227-13-00 1 country 2023 n=112
    Recruiting
  • Salubris Biotherapeutics Inc. Commercial
    JK06
    2024-512421-92-00 2 countries 2025 n=305
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AbbVie Deutschland GmbH & Co. KG Commercial 5 Phase III/IV, Phase I (Other), Phase II, Phase I (First in Human) 4
Merck Healthcare KGaA Commercial 1 Phase I 0
Seagen Inc. Commercial 1 Phase I 0
Zymeworks Inc. Commercial 1 Phase I 1
Debiopharm International S.A. Commercial 1 Phase I (Other) 0
Exelixis Inc. Commercial 1 Phase I (Other) 0
F. Hoffmann-La Roche AG Commercial 1 Phase II 0
AstraZeneca AB Commercial 1 Phase III 1
Immunogen Inc. Commercial 1 Phase III 0
Merck Sharp & Dohme LLC Commercial 1 Phase III 0
pharmaand GmbH Commercial 1 Phase III 0
858 Therapeutics Inc. Commercial 1 Phase I (First in Human) 0
BioNTech SE Commercial 1 Phase I (First in Human) 1
Exscientia AI Limited Commercial 1 Phase I (First in Human) 1
Salubris Biotherapeutics Inc. Commercial 1 Phase I (First in Human) 1
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic 1 Phase II 0
Arcagy Gineco Academic 1 Phase III 1
Swiss GO Trial Group Academic 1 Phase III 1
Hospices Civils De Lyon Academic 1 Phase IV 0
New trials by year
2020
1
2021
2
2022
1
2023
5
2024
4
2025
3
2026
3
← All indication landscapes